Proton pump inhibitors and the risk of Clostridium difficile-associated disease: Further evidence from the community

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 7, 2006, Pages 757-758

  Cunningham, Richard ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT; PROTON PUMP; VANCOMYCIN;

BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; NOTE; PATHOGENESIS; RISK ASSESSMENT; COMMUNICABLE DISEASE; DRUG ANTAGONISM; PRESCRIPTION; PSEUDOMEMBRANOUS COLITIS; RISK; RISK FACTOR; STATISTICS; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COMMUNITY-ACQUIRED INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GREAT BRITAIN; HUMANS; ODDS RATIO; PRESCRIPTIONS, DRUG; PROTON PUMPS; RISK FACTORS; VANCOMYCIN;

EID: 33749329801     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060919     Document Type: Note

References (11)

1. Archibald LK, Banerjee SH, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004;189: 1585-9.
2. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171(5):466-72.
3. Health Protection Agency. Reports of Clostridium difficile isolated from faecal specimens under the voluntary reporting scheme: England, Wales, and Northern Ireland 1990-2004. London: The Agency. Available: www.hpa.org.uk/ infections /topics_az/clostridium_difficile/vol_data.htm (accessed 2006 Aug 17).
4. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
5. Pépin J, Saheb N, Coulombe M, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
6. Beaulieu M, Thirion DJG, Williamson D, et al. Clostridium difficile-associated diarrhea outbreaks: The name of the game is isolation and cleaning. Clin Infect Dis 2006;42:725.
7. Weiss K. Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec. Clin Infect Dis 2006;42:725-7.
8. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-5.
9. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8.
10. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95.
11. Dial S, Delaney JAC, Schneider V, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CAMJ 2006;175(7):745-8.